Delving into the Latest Updates on sE2-cVLP HCV vaccine(ExpreS2ion) with Synapse

Overview

Basic Info

Drug Type

Virus-like particle vaccine, Prophylactic vaccine

Synonyms-

Target

HCV E2

Mechanism

HCV E2 inhibitors(HCV E2 inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis, Viral, Human

Inactive Indication-

Originator Organization

Expres2ion Biotech Holding AB

Active Organization

Expres2ion Biotech Holding AB

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

AbstractDevelopment of B-cell-based hepatitis C virus (HCV) vaccines that induce broadly neutralizing antibodies (bNAbs) is hindered by extensive sequence diversity and low immunogenicity of envelope glycoprotein vaccine candidates, most notably soluble E2 (sE2). To overcome this, we employed two-component approaches using self-assembling virus-like particles (cVLPs; component 1), displaying monomeric or oligomeric forms of HCV sE2 (sE2mono or sE2oligo; component 2). Immunization studies were performed in BALB/c mice and the neutralizing capacity of vaccine-induced antibodies was tested in cultured-virus-neutralizations, using HCV of genotypes 1–6. sE2-cVLP vaccines induced significantly higher levels of NAbs (p = 0.0065) compared to corresponding sE2 vaccines. Additionally, sE2oligo-cVLP was superior to sE2mono-cVLP in inducing bNAbs. Interestingly, human monoclonal antibody AR2A had reduced binding in ELISA to sE2oligo-cVLP compared with sE2mono-cVLP and competition ELISA using mouse sera from vaccinated animals indicated that sE2oligo-cVLP induced significantly less non-bNAbs AR2A (p = 0.0043) and AR1B (p = 0.017). Thus, cVLP-displayed oligomeric sE2 shows promise as an HCV vaccine candidate.

100 Deals associated with sE2-cVLP HCV vaccine(ExpreS2ion)

Login to view more data